Expand QURE Menu
QURE MENU

QURE Latest Press Releases

-- September 2, 2026 --

uniQure Announces Submission of Biologics License Application for Ifezuntirgene Inilparvovec (AMT-130) in Huntington's Disease Globe Newswire 7:05 AM

-- July 29, 2026 --

uniQure Announces Second Quarter 2026 Financial Results and Provides Company Update Globe Newswire 7:05 AM

-- July 22, 2026 --

uniQure to Announce Second Quarter 2026 Financial Results Globe Newswire 7:05 AM

-- June 25, 2026 --

uniQure Announces Closing of Upsized Public Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares Globe Newswire 4:10 PM

-- June 23, 2026 --

uniQure Announces Pricing of Upsized $225 Million Public Offering Globe Newswire 9:13 PM

-- June 22, 2026 --

uniQure Announces $150 Million Proposed Public Offering Globe Newswire 4:01 PM

-- June 19, 2026 --

uniQure Announces Preliminary Data on the First Cohort in the Phase I/IIa Clinical Trial of AMT-260 in Refractory Mesial Temporal Lobe Epilepsy Globe Newswire 7:05 AM

-- June 17, 2026 --

Biotech's New Frontier: Companies Breaking Through Medicine's Toughest Barriers Globe Newswire 10:37 AM
uniQure Announces Plan for BLA Submission for AMT-130 in Huntington's Disease Globe Newswire 7:05 AM

-- May 5, 2026 --

uniQure Announces First Quarter 2026 Financial Results and Provides Recent Company Updates Globe Newswire 7:05 AM

-- April 30, 2026 --

uniQure Announces Successful UK MHRA Pre-Submission Meeting for AMT-130 in Huntington's Disease Globe Newswire 7:05 AM

-- April 28, 2026 --

uniQure to Announce First Quarter 2026 Financial Results Globe Newswire 7:05 AM
Market Data Delayed 15 Minutes